Status:
RECRUITING
Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma
Lead Sponsor:
Tanta University
Conditions:
Hepato Cellular Carcinoma (HCC)
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this prospective cohort study is to evaluate the role of transient elastography (Fibroscan) in predicting the response of immunotherapy in advanced Hepatocellular carcinoma (HCC) patients....
Eligibility Criteria
Inclusion
- Patients with confirmed advanced HCC (Diagnosed by two imaging modalities or liver biopsy) eligible for immunotherapy.
- Patients with preserved liver function (compensated Child-Pugh A if there is underlying cirrhosis).
- Patients with performance status ≤2 at staging work-up.
- absence of high-risk stigmata for bleeding on upper endoscopy, e.g. properly treated oesophageal varices and no history of variceal bleeding, in order to minimise bleeding risk.
Exclusion
- Prior locoregional therapy or liver transplantation.
- Child-Pugh class C patients.
- Patients with performance status \>2 at staging work-up.
- Vascular disorders, arterial hypertension, and risk of variceal bleeding.
- Severe autoimmune disorders.
- Patients who lost follow-up.
- Pregnant or breastfeeding women.
- Unwilling to participate in our study.
Key Trial Info
Start Date :
January 26 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06960863
Start Date
January 26 2025
End Date
January 31 2026
Last Update
May 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tanta University Hospitals
Tanta, Gharbyea, Egypt, 31516